Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
13.74
+0.09 (0.66%)
At close: May 12, 2025, 4:00 PM
14.00
+0.26 (1.89%)
After-hours: May 12, 2025, 6:51 PM EDT
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $211.25M in the quarter ending March 31, 2025, with 254,413.25% growth. This brings the company's revenue in the last twelve months to $214.71M, up 91,657.69% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$214.71M
Revenue Growth
+91,657.69%
P/S Ratio
2.47
Revenue / Employee
$1,270,491
Employees
169
Market Cap
558.06M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KROS News
- 11 hours ago - ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth - PRNewsWire
- 16 hours ago - Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference - GlobeNewsWire
- 4 days ago - Keros Reinforces Commitment to Maximizing Stockholder Value - GlobeNewsWire
- 4 days ago - ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - PRNewsWire
- 6 days ago - Keros Therapeutics Reports Recent First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Benzinga
- 4 weeks ago - Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
- 4 weeks ago - Keros Therapeutics adopts 'poison pill' plan - Reuters